Index RUT
P/E 4.06
EPS (ttm) 0.70
Insider Own 29.83%
Shs Outstand 67.71M
Perf Week -0.35%
Market Cap 193.65M
Forward P/E -
EPS next Y -1.09
Insider Trans -0.14%
Shs Float 47.51M
Perf Month -85.39%
Income 49.27M
PEG -
EPS next Q -0.00
Inst Own 89.52%
Short Float 10.72%
Perf Quarter -80.33%
Sales 380.79M
P/S 0.51
EPS this Y -283.95%
Inst Trans 32.53%
Short Ratio 1.74
Perf Half Y -84.71%
Book/sh 6.40
P/B 0.45
EPS next Y 15.49%
ROA 10.84%
Short Interest 5.09M
Perf Year -90.63%
Cash/sh 5.48
P/C 0.52
EPS next 5Y -
ROE 12.73%
52W Range 2.67 - 31.77
Perf YTD -80.57%
Dividend Est. -
P/FCF 18.13
EPS past 5Y -
ROI 11.32%
52W High -91.00%
Beta -0.92
Dividend TTM -
Quick Ratio 5.20
Sales past 5Y 2300.59%
Gross Margin 93.03%
52W Low 7.12%
ATR (14) 0.89
Dividend Ex-Date -
Current Ratio 5.66
EPS Y/Y TTM 130.51%
Oper. Margin 10.19%
RSI (14) 21.48
Volatility 6.34% 10.00%
Employees 384
Debt/Eq 0.01
Sales Y/Y TTM 1612.94%
Profit Margin 12.94%
Recom 2.50
Target Price 5.14
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q 110.48%
Payout 0.00%
Rel Volume 0.55
Prev Close 2.88
Sales Surprise 1.39%
EPS Surprise -69.27%
Sales Q/Q 395.54%
Earnings Feb 22 BMO
Avg Volume 2.92M
Price 2.86
SMA20 -63.50%
SMA50 -77.43%
SMA200 -83.29%
Trades
Volume 1,207,710
Change -0.69%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-18-24 Downgrade
Mizuho
Buy → Neutral
$32 → $4
Mar-11-24 Downgrade
Robert W. Baird
Outperform → Neutral
$37 → $4
Mar-11-24 Downgrade
Leerink Partners
Outperform → Market Perform
$27 → $4
Mar-08-24 Downgrade
Goldman
Buy → Neutral
Mar-08-24 Downgrade
Evercore ISI
Outperform → In-line
Jan-03-24 Initiated
Robert W. Baird
Outperform
$37
Dec-12-23 Initiated
Deutsche Bank
Buy
$36
Jul-24-23 Upgrade
Goldman
Neutral → Buy
$45 → $49
Mar-31-23 Initiated
Mizuho
Buy
$52
Jan-05-23 Initiated
BofA Securities
Buy
$50
May-25-22 Initiated
Citigroup
Buy
$21
Apr-01-22 Downgrade
Goldman
Buy → Neutral
$36 → $10
Show Previous Ratings
Mar-27-24 07:36AM
Mar-25-24 02:33PM
Mar-14-24 06:49PM
09:00AM
Mar-13-24 10:00AM
09:03AM
Loading…
09:03AM
Mar-12-24 07:55AM
Mar-11-24 12:34PM
07:45AM
Mar-10-24 08:00AM
(The Wall Street Journal)
Mar-08-24 06:27PM
04:05PM
(Investor's Business Daily)
11:30AM
(Associated Press Finance)
10:20AM
10:12AM
(Investor's Business Daily)
09:38AM
Loading…
09:38AM
09:26AM
07:07AM
07:00AM
02:05AM
Feb-27-24 05:45AM
Feb-26-24 11:39AM
Feb-25-24 06:30AM
Feb-23-24 04:05PM
10:30AM
10:10AM
09:00AM
05:45AM
Feb-22-24 06:57PM
04:10PM
(Investor's Business Daily)
08:15AM
Loading…
08:15AM
07:35AM
07:00AM
Feb-20-24 05:45AM
Feb-19-24 12:40PM
Feb-15-24 04:05PM
02:13PM
09:00AM
Feb-13-24 09:16PM
12:58PM
Feb-12-24 08:09PM
11:09AM
Feb-08-24 09:00AM
Jan-26-24 03:57PM
Jan-21-24 01:16PM
Jan-14-24 12:54PM
Jan-05-24 05:34AM
Dec-26-23 07:02PM
08:48AM
Dec-22-23 09:00AM
Dec-11-23 08:36AM
Dec-04-23 09:00AM
Nov-29-23 05:15PM
Nov-28-23 08:48AM
07:00AM
Nov-27-23 09:00AM
Nov-21-23 09:00AM
Nov-12-23 11:59AM
Nov-10-23 12:26AM
(Thomson Reuters StreetEvents)
Nov-09-23 05:04PM
(Investor's Business Daily) -31.89%
12:12PM
(Investor's Business Daily)
08:05AM
07:00AM
Nov-04-23 12:16PM
Nov-02-23 10:00AM
09:00AM
Oct-19-23 09:00AM
Oct-18-23 08:30AM
Oct-13-23 08:26AM
07:55AM
07:45AM
Oct-11-23 08:07AM
Oct-10-23 09:45AM
09:12AM
Oct-05-23 05:26PM
Oct-02-23 09:00AM
Sep-29-23 12:43PM
02:54AM
Sep-20-23 09:02AM
Sep-05-23 09:00AM
Aug-28-23 11:53PM
Aug-14-23 05:38AM
(American City Business Journals)
Aug-13-23 08:26AM
Aug-11-23 08:47AM
(Thomson Reuters StreetEvents)
Aug-10-23 05:15PM
04:01PM
Aug-03-23 04:05PM
Jul-28-23 12:56PM
09:19AM
Jul-24-23 12:17PM
Jul-19-23 05:00AM
Jul-12-23 09:00AM
Jun-27-23 10:57AM
Jun-26-23 10:36AM
Jun-23-23 11:27AM
08:14AM
Jun-15-23 09:00AM
Jun-13-23 11:15AM
Jun-12-23 06:53AM
Jun-06-23 09:00AM
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Klee Justin B. Co-Chief Executive Officer Mar 05 '24 Sale 18.73 4,135 77,440 2,959,308 Mar 07 04:05 PM Cohen Joshua B Co-Chief Executive Officer Mar 05 '24 Sale 18.73 4,135 77,440 3,023,002 Mar 07 04:05 PM FRATES JAMES M Chief Financial Officer Mar 05 '24 Sale 18.73 1,792 33,560 134,784 Mar 07 04:05 PM Mazzariello Gina Chief Legal Officer Mar 05 '24 Sale 18.73 1,540 28,841 81,372 Mar 07 04:05 PM Mazzariello Gina Chief Legal Officer Feb 23 '24 Sale 18.76 2,838 53,231 46,245 Feb 27 05:59 PM Klee Justin B. Co-Chief Executive Officer Jan 09 '24 Sale 16.33 5,841 95,372 2,836,776 Jan 11 05:11 PM Cohen Joshua B Co-Chief Executive Officer Jan 09 '24 Sale 16.33 5,841 95,372 2,900,470 Jan 11 05:10 PM Yeramian Patrick D Chief Medical Officer Jan 09 '24 Sale 16.33 2,812 45,915 205,605 Jan 11 05:04 PM FRATES JAMES M Chief Financial Officer Jan 09 '24 Sale 16.33 2,716 44,347 112,035 Jan 11 05:11 PM Olinger Margaret Chief Commercial Officer Dec 27 '23 Option Exercise 0.37 25,000 9,250 276,108 Dec 29 04:07 PM Firestone Karen Director Dec 15 '23 Buy 14.97 4,000 59,880 5,000 Dec 19 04:37 PM Cohen Joshua B Co-Chief Executive Officer Nov 16 '23 Option Exercise 1.57 63,694 100,000 2,906,311 Nov 20 08:20 PM FRATES JAMES M Chief Financial Officer Aug 23 '23 Option Exercise 6.88 18,165 124,975 106,341 Aug 24 04:15 PM Mazzariello Gina Chief Legal Officer Aug 15 '23 Sale 20.88 6,164 128,686 49,083 Aug 17 04:35 PM Olinger Margaret Chief Commercial Officer Jul 12 '23 Option Exercise 0.37 20,000 7,400 251,108 Jul 14 04:20 PM FRATES JAMES M Chief Financial Officer May 16 '23 Option Exercise 6.88 32,500 223,600 88,176 May 18 08:54 PM FRATES JAMES M Chief Financial Officer May 16 '23 Sale 26.94 32,500 875,451 55,676 May 18 08:54 PM Yeramian Patrick D Chief Medical Officer May 15 '23 Option Exercise 5.68 11,965 67,991 220,382 May 17 04:58 PM Yeramian Patrick D Chief Medical Officer May 15 '23 Sale 29.03 11,965 347,358 208,417 May 17 04:58 PM Yeramian Patrick D Chief Medical Officer Apr 17 '23 Option Exercise 0.99 49,579 49,058 257,996 Apr 19 07:45 PM Yeramian Patrick D Chief Medical Officer Apr 17 '23 Sale 30.54 49,579 1,513,942 208,417 Apr 19 07:45 PM Morningside Venture Investment 10% Owner Mar 29 '23 Sale 30.45 29,048 884,512 6,997,302 Mar 31 04:05 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite